{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:13:14Z","timestamp":1790190794537,"version":"4.1.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T00:00:00Z","timestamp":1470268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0159993","type":"journal-article","created":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T13:42:44Z","timestamp":1470318164000},"page":"e0159993","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":47,"title":["Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study"],"prefix":"10.1371","volume":"11","author":[{"given":"P. R.","family":"Bourque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. E.","family":"Pringle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Warman","family":"Chardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,8,4]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1055\/s-0032-1329200","article-title":"Myasthenia gravis","volume":"32","author":"NJ Silvestri","year":"2012","journal-title":"Semin Neurol"},{"issue":"12","key":"ref2","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1586\/1744666X.2014.971757","article-title":"Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes","volume":"10","author":"M Alabdali","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(95)90346-1","article-title":"Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs","volume":"345","author":"A Gardulf","year":"1995","journal-title":"Lancet"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/1756285615584739","article-title":"Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders","volume":"8","author":"MS Yoon","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"issue":"7","key":"ref5","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"GI Wolfe","year":"1999","journal-title":"Neurology"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/mus.21053","article-title":"Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis","volume":"38","author":"TM Burns","year":"2008","journal-title":"Muscle Nerve"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1212\/WNL.0b013e31827b907b","article-title":"Complete stable remission and autoantibody specificity in myasthenia gravis","volume":"80","author":"F Baggi","year":"2013","journal-title":"Neurology"},{"issue":"5\u20136","key":"ref8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/08916930903518107","article-title":"Immunosuppressive therapies in myasthenia gravis","volume":"43","author":"DB Sanders","year":"2010","journal-title":"Autoimmunity"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/mus.24259","article-title":"Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulation","volume":"50","author":"C Eienbr\u00f6ker","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIG and PLEX in patients with myasthenia gravis","volume":"76","author":"D Barth","year":"2011","journal-title":"Neurology"},{"issue":"9","key":"ref11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","article-title":"EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases","volume":"15","author":"I Elovaara","year":"2008","journal-title":"Eur J Neurol"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002277.pub4","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"12","author":"P Gajdos","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/1756285615605700","article-title":"Future perspectives in target-specific immunotherapies of myasthenia gravis","volume":"8","author":"MC Dalakas","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamaneurol.2014.17","article-title":"Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis","volume":"71","author":"WK Liew","year":"2014","journal-title":"JAMA Neurol"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<551::AID-MUS14>3.0.CO;2-O","article-title":"Immunoglobulin treatment in refractory Myasthenia gravis","volume":"23","author":"A Achiron","year":"2000","journal-title":"Muscle Nerve."},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2004.02.002","article-title":"Subcutaneous immunoglobulin replacement in primary immunodeficiencies","volume":"112","author":"M Berger","year":"2004","journal-title":"Clin Immunol"},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/s10875-012-9720-1","article-title":"Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta-analysis","volume":"32","author":"H Abolhassani","year":"2012","journal-title":"J Clin Immunol"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-3148.2012.01201.x","article-title":"Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency","volume":"23","author":"A Martin","year":"2013","journal-title":"Transfus Med"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.iac.2008.07.002","article-title":"Subcutaneous administration of IgG","volume":"28","author":"M Berger","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10875-006-8905-x","article-title":"Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home","volume":"26","author":"U Nicolay","year":"2006","journal-title":"J Clin Immunol"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/ene.12080","article-title":"Danish CIDP and MMN Study Group. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"20","author":"LH Markvardsen","year":"2013","journal-title":"Eur J Neurol"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/mus.20909","article-title":"Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy","volume":"37","author":"DH Lee","year":"2008","journal-title":"Muscle Nerve"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1529-8027.2011.00330.x","article-title":"A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study","volume":"16","author":"SA Misbah","year":"2011","journal-title":"J Peripher Nerv Syst"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1529-8027.2009.00218.x","article-title":"Subcutaneous immunoglobulin therapy for multifocal motor neuropathy","volume":"14","author":"F Eftimov","year":"2009","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1468-1331.2009.02568.x","article-title":"Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial","volume":"16","author":"T Harbo","year":"2009","journal-title":"Eur J Neurol"},{"issue":"15","key":"ref26","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1212\/WNL.0b013e3181f735ce","article-title":"Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy","volume":"75","author":"T Harbo","year":"2010","journal-title":"Neurology"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.autrev.2015.12.003","article-title":"Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases","volume":"15","author":"P Cherin","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2010.09.004","article-title":"Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application","volume":"10","author":"MG Danieli","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10067-013-2478-x","article-title":"Open-label study on treatment with 20% subcutaneous IgG administration in polymyositis and dermatomyositis","volume":"33","author":"MG Danieli","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"8","key":"ref30","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s10067-008-0892-2","article-title":"Subcutaneous immunoglobulin administration: an alternative to intravenous infusion as adjuvant treatment for dermatomyositis?","volume":"27","author":"N Schleinitz","year":"2008","journal-title":"Clin Rheumatol"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2217\/imt.13.146","article-title":"Subcutaneous IgG in neurologic diseases","volume":"6","author":"M Berger","year":"2014","journal-title":"Immunotherapy"},{"key":"ref32","article-title":"Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases","author":"P Cherin","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"6","key":"ref33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/11587030-000000000-00000","article-title":"Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency","volume":"50","author":"RL Wasserman","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10875-011-9631-6","article-title":"Higher doses of subcutaneous IgG reduce resource utilization in patients with primary immunodeficiency.","volume":"32","author":"E Haddad","year":"2012","journal-title":"J Clin Immunol."},{"issue":"11","key":"ref35","doi-asserted-by":"crossref","first-page":"e0142205","DOI":"10.1371\/journal.pone.0142205","article-title":"A Retrospective Longitudinal Within-Subject Risk Interval Analysis of Immunoglobulin Treatment for Recurrent Acute Exacerbation of Chronic Obstructive Pulmonary Disease","volume":"10","author":"J Cowan","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"ref36","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1212\/01.WNL.0000163988.28892.79","article-title":"Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity","volume":"64","author":"RS Bedlack","year":"2005","journal-title":"Neurology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0159993","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T05:05:01Z","timestamp":1589000701000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0159993"}},"subtitle":[],"editor":[{"given":"G\u00fcher","family":"Saruhan-Direskeneli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,8,4]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0159993","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,4]]}}}